

In Vitro and *In Silico* Evaluation of Compounds from *Washingtonia filifera* as Acetylcholinesterase Inhibitors

Aalaa Salem ¹, Fatma M. Abdel Bar ^{2,3*}, El-Sayed M. Marwan ¹,
Amal F. Soliman ^{1,4}, Saleh H. El-Sharkawy ^{1,5} and Amira Mira ^{1,6}

¹Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University Mansoura 35516, Egypt

²Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia

³Faculty of Pharmacy, Mansoura University Mansoura 35516, Egypt

⁴Pharmacognosy Department, Faculty of Pharmacy, Mansoura National University, Gamasa 7731168, Egypt

⁵Department of Basic Sciences, Faculty of Physical Therapy, Rashid University, Rashid 5965022, Egypt

⁶Department of Pharmacognosy & Pharmaceutical Chemistry, College of Dentistry & Pharmacy, Buraydah Colleges, Buraydah 51418, Saudi Arabia

(Received April 06, 2025; Revised June 20, 2025; Accepted June 22, 2025)

Abstract: Nine known compounds were isolated from the fruitless bunches of *Washingtonia filifera*, an underutilized agricultural waste, using NMR and mass spectrometry. The identified compounds included β -sitosterol oleate (**1**), oleic acid (**2**), β -sitosterol (**3**), *threo*-2,3-bis-(4-hydroxy-3-methoxyphenyl)-3-methoxypropanol (**4**), syringaresinol (**5**), diosmetin (**6**), tricin (**7**), daucosterol (**8**), and luteolin-7-O- β -D-glucoside (cynaroside) (**9**). *In vitro* acetylcholinesterase (AChE) inhibition assays revealed that compound **5** exhibited the strongest activity ($IC_{50} = 29.75 \mu M$), followed by compounds **4** and **6**. Docking studies indicated significant interactions of the active compounds with key AChE residues, particularly Trp86 and Tyr341. ADME predictions further supported the drug-likeness of compounds **4** and **5**. These results highlight the significance of *W. filifera* agricultural waste as a source of bioactive compounds, particularly with neuroprotective effects.

Keywords: *Washingtonia filifera*; californian fan palm; fruitless bunch; acetylcholinesterase; phenolics; lignan.
© 2025 ACG Publications. All rights reserved.

1. Plant Source

Limited studies have been conducted on the agricultural waste of *W. filifera*, particularly the plant grown in Egypt. This study investigated the phytochemical composition of fruitless bunches of *Washingtonia filifera* (Linden ex André) H. Wendl., an underexplored agricultural waste, particularly in Egypt. Samples were collected from the garden of the Faculty of Pharmacy, Mansoura University, on November 24, 2022, and identified by Assoc. Prof. Dr. Mahmoud Makram Qassem. A voucher

* Corresponding author: E-Mail: f.abdelbar@psau.edu.sa; Phone: 00966-545403617

Compounds from *Washingtonia filifera* as acetylcholinesterase inhibitors

specimen (WF-1-2020) is deposited in the Pharmacognosy Department, Faculty of Pharmacy, Mansoura University.

2. Previous Studies

The aerial parts of *W. filifera* showed the presence of flavonols, C-glycosyl flavones, and flavonoid sulfates. While flavonoid sulfates are rare in plants, they are present in several palm species, particularly *Washingtonia*. The plant contains chalconoids (chalcone-like compounds) in its leaf basal tissues, which exhibit antilarval activity, antioxidative, antimalarial, and anticancer activities [1]. Previous reports showed that the alcoholic seed extract of *W. filifera* exhibited strong antioxidant and enzyme inhibitory properties towards various enzymes involved in aging-related disorders, such as butyrylcholinesterase, xanthine oxidase, elastase, collagenase, and tyrosinase [2,3]. However, there is no previous research on the AChEI activity of the other parts of *W. filifera* or for the pure isolated compounds.

3. Present Study

Extraction and Isolation: The shade-dried powdered fruitless bunches of *W. filifera* (5 Kg) were extracted with 70% methanol (MeOH) at room temperature (25°C) (3 × 12 L) and evaporated *in vacuo* to yield 500 g of total fruitless bunches extract (TFBE). This residue was dissolved in the minimum amount of MeOH, diluted with 700 mL of distilled water, and then fractionated using solvents of increasing polarity to provide a petroleum ether fraction (PEF, 90 g), CH₂Cl₂ fraction (MCF, 31 g), EtOAc fraction (EAF, 24 g), and *n*-butanol fraction (BUF, 22 g). About 50 grams of PEF fraction were purified on a silica gel CC packed in petroleum ether, eluted with petroleum ether/ EtOAc (gradient), to afford two major groups. Group I (F88-96), eluted with petroleum ether/ EtOAc (98.5:1.5, v/v), was further purified over a silica gel CC by gradient elution with petroleum ether/ EtOAc to afford two subgroups. Subgroup I-a (F101-103), eluted with petroleum ether/ EtOAc (99.5:0.5, v/v), was further purified on a silica gel CC, previously packed in petroleum ether, using isocratic elution with petroleum ether/ CH₂Cl₂ (70:30, v/v) to afford compound **1** (40 mg) in fractions (F4-10). Subgroup I-b (F297-324), eluted with petroleum ether/ EtOAc (98:2, v/v), was concentrated to yield an oily residue (Compound **2**, 1.4 g). Group II (F173-209) eluted with petroleum ether/ EtOAc (90:10, v/v) were concentrated to yield colorless needles (Compound **3**, 213 mg). The MCF fraction (31 g) was further purified using the VLC technique using different solvents (Petroleum ether, CH₂Cl₂, and MeOH). Fraction 7 (13 g), eluted with CH₂Cl₂/ MeOH (10:1, v/v), was further purified by a silica gel CC previously packed in CH₂Cl₂. Gradient elution with CH₂Cl₂/ MeOH afforded three groups (Groups I-III). Group I (F145-168), eluted with CH₂Cl₂/ MeOH (99.5:0.5, v/v), was further purified by a Sephadex LH-20 CC previously packed in CH₂Cl₂/ MeOH (50:50, v/v) using isocratic elution to afford two subgroups. Subgroup I-a (F22-24), eluted with CH₂Cl₂-MeOH (50:50, v/v) on Sephadex LH-20, was further purified over a Sephadex LH-20 CC previously packed in MeOH/ distilled H₂O (50:50, v/v) using isocratic elution to afford two subgroups (I-a1 and I-a2). Subgroup I-a1 (F23-26) was purified over a Sephadex LH-20 CC using MeOH (100 %) to afford a brown solid residue (Compound **4**, 8 mg). Subgroup I-a2 (F29-37) was purified over a silica gel CC using gradient elution with petroleum ether/EtOAc. Subfractions 106-129, eluted with petroleum ether/ EtOAc (40:60, v/v) yielded a brown solid residue (Compound **5**, 11 mg). Subgroup I-b (F32-39), eluted with CH₂Cl₂/ MeOH (50:50, v/v) on Sephadex LH-20, yielded a pale-yellow powder (Compound **6**, 7 mg). Group II (F169-181), eluted with CH₂Cl₂/ MeOH (99:1, v/v) yielded a yellow powder (Compound **7**, 30 mg). Group III (F252-277), eluted with CH₂Cl₂/ MeOH (96:4, v/v) yielded a white powder (Compound **8**; 134 mg). The BUF fraction (22 g) was purified on a silica gel CC eluted with CH₂Cl₂/ MeOH (gradient). Fractions (F38-44) eluted with CH₂Cl₂-MeOH (80:20, v/v) were pooled and repeatedly purified over Sephadex LH-20 CC using MeOH/ distilled H₂O (50:50, v/v) to afford a yellow powder (Compound **9**; 10 mg).

In vitro AChE Inhibitory Assay: The AChE inhibition of was assessed using a modified Ellman's method [4]. Briefly, in each well of a 96-well plate, 25 μ L of acetylthiocholine iodide (15 mM), 125 μ L of DTNB (3 mM in buffer B), 50 μ L of buffer A, and 25 μ L of the test sample (prepared in DMSO, 25%) were combined. Absorbance was recorded at 405 nm using a BioTek® microplate reader (Winooski, VT, USA) at 16-second intervals for a total of ten readings. Subsequently, 25 μ L of AChE (0.25 U/mL in buffer A) was introduced, and absorbance measurements were repeated ten times at the same intervals. A 25% DMSO solution served as the negative control.

Docking Study: The protein structure used in this study was the crystal structure (Resolution: 2.35 Å) of recombinant human acetylcholinesterase complexed with donepezil, obtained from the Protein Data Bank (PDB ID: 4EY7) [5]. Docking studies were carried out using MOE software (version 2015.10) from Chemical Computing Group Inc. according to the previously published procedure [6].

Prediction of ADME and Drug-Likeness Properties of Compounds 1-9: The physicochemical characteristics, pharmacokinetics, drug-likeness, and toxicity of the studied compounds (**1-9**) were analyzed using the SwissADME tool, provided by the Swiss Institute of Bioinformatics (<http://www.sib.swiss>) [7].




Figure 1. Structures of the isolated compounds (**1-9**) from *W. filifera* fruitless bunches

Compound **1** (Figure 1) was identified as β -sitosteryl oleate based on ¹H-NMR, APT, HMBC, and mass spectral data (Table S1; Figures S2-S4), consistent with literature [8]. Compound **2** was confirmed as oleic acid via ¹H-NMR, APT, and mass spectral data (Table S2; Figures S5-S7) [9], a compound previously identified in the seed oil of *W. filifera* [10,11] and the fruit oil of *W. robusta* [12]. Compound **3** was verified as β -sitosterol using IR spectrum (Figure S8) and co-chromatography with an authentic standard [12]. Compound **4** was identified as 9-hydroxy-7-methoxy-8-[4'-hydroxy-3'-methoxyphenyl]-4-hydroxy-3-methoxyphenylpropane, also named 2,3-bis-(4-hydroxy-3-methoxyphenyl)-3-methoxypropanol based on ¹H-NMR, APT, HSQC, HMBC, and ESI-MS (Table S3; Figures S9-S13). This compound has been reported from various plant sources, including *Aralia bipinnata* [13], *Irvingia malayana* [14], and *Solanum melongena* [15]. The stereochemistry of compound **4** was determined to be the *threo* isomer based on a comparison of its ¹³C chemical shifts (δ_c) with those reported by Yang et al. [15] for both *erythro* and *threo* configurations. Specifically, the chemical shift of carbon C-7 in compound **4** was observed at 87.42 ppm, closely corresponding to that of the *threo* isomer (87.4 ppm) and differing from the *erythro* isomer (δ_c 84.9 ppm). Compound **5** was

Compounds from *Washingtonia filifera* as acetylcholinesterase inhibitors

identified as syringaresinol, supported by its $^1\text{H-NMR}$, APT, HSQC, and ESI-MS spectral data (Table S4; Figures S14-S17) [16]. Compound **6** was elucidated as diosmetin (5,7,3'-trihydroxy-4'-methoxyflavone) based on comprehensive spectral analysis, including $^1\text{H-NMR}$ (Table S5; Figures S18, S19), APT spectrum (Table S5; Figure S20), HSQC, and HMBC spectra (Figures S21-S23) [17]. Compound **7** was identified as tricin (5,7,4'-trihydroxy-3',5'-dimethoxyflavone), as evidenced by its $^1\text{H-NMR}$ (Table S6; Figure S24), APT (Table S6; Figure S25), HSQC (Figure S26) and HMBC (Figure S27) spectra [18]. This compound has previously been reported in *W. filifera* leaves [19]. Compound **8** was characterized as β -sitosterol-3-O- β -D-glucoside based on its IR spectral data (Figure S28) and confirmed by co-chromatography with an authentic standard [20]. Finally, compound **9** was identified as luteolin 7-O- β -D-glucoside through analysis of its $^1\text{H-NMR}$, APT, HSQC, and HMBC spectral data (Table S7; Figures S29-S32) [21]. These findings significantly contribute to the chemotaxonomic understanding of the genus *Washingtonia* and the family Arecaceae by documenting several compounds for the first time. β -Sitosteryl oleate (**1**), luteolin-7-O- β -D-glucoside (**9**), syringaresinol (**5**), diosmetin (**6**), and daucosterol (**8**) are reported here for the first time in the *Washingtonia* genus. Notably, compound **4** [*threo*-2,3-bis-(4-hydroxy-3-methoxyphenyl)-3-methoxypropanol] is reported here for the first time from the Arecaceae family.

The results of AChE inhibition assay of the isolated compounds (Table 1) revealed that compound **5** (syringaresinol) showed the strongest inhibitory activity against AChE among the isolated compounds with an IC_{50} of 29.75 μM , followed by compound **4** (IC_{50} of 72.49 μM) and **6** (IC_{50} of 76.90 μM). Lignans were previously reported to exhibit protective effects against neurodegenerative diseases, such as AD, Parkinson's, stroke, and other conditions linked to neuronal cell damage [22,23]. Acetylcholinesterase inhibition was previously reported as one of the mechanisms through which lignans exert neuroprotective effects against Alzheimer's disease (AD). On the other hand, compounds **7** (tricin) and **9** (cynaroside) showed modest activity. However, compounds **8** (β -sitosterol-3-O- β -D-glucoside), **2** (oleic acid), and **3** (β -sitosterol) showed weak activity. Whereas compound **1** (β -sitosteryl oleate) exhibited the lowest inhibitory activity.

Table 1. AChE inhibitory activity and docking results of compounds **1-9** against AchE protein

Compound	IC_{50} (μM)	Score (kcal/mol)	RMSD ^b	Interactions ^c
1	> 100 ^a	-10.9898	1.4618	
2	> 100 ^a	-7.6073	1.4174	Trp86, Arg296
3	> 100 ^a	-7.6745	1.5253	Trp86, Glu202, Tyr133
4	72.49 $\pm$ 1.24	-7.6684	0.8996	Trp86, Tyr341
5	29.75 $\pm$ 0.69	-8.0811	1.7034	Trp86, Tyr341
6	76.90 $\pm$ 4.57	-6.5626	1.0250	Phe295, Tyr341
7	> 100 (166.21 $\pm$ 8.21)	-6.9222	1.0912	Ser203, Trp286, Tyr341
8	> 100 ^a	-8.1962	1.3087	Trp86
9	> 100 (360.01 $\pm$ 11.02)	-8.3806	1.4742	Ser203, Ser293, Tyr341
Donepezil ^d		-8.3431	1.2587	Trp86, Trp286, Tyr337
Donepezil ^e				Trp86, Trp286, Phe295
TFBE	89.60 $\pm$ 3.15			
Galanthamine	1.44 $\pm$ 0.25			

^a Inactive up to concentration of 500 μM ; ^b RMSD: Root mean square deviation. A value < 2 Å suggests acceptable; docking result; ^c Acetylcholinesterase (AChE) protein, PDB code: 4EY7 [5]; ^d Donepezil (docked ligand); ^e Donepezil (co-crystallized ligand). TFBE: Total fruitless bunches extract.

To explain the results of the *in vitro* AChE assay, a docking study of isolated compounds (**1-9**) with human AChE at its active site (PDB code 4EY7) was conducted (Table 1). Cheung et al. (2012) described the structural details of the human AChE binding site, emphasizing the unique conformations of its active site residues, particularly Trp86, Tyr337, Tyr341, and Phe338, which play a critical role in ligand binding [5]. Donepezil, a standard AChE inhibitor, showed strong interactions involving π - π stacking with Trp86 and Trp286, similar to the observations in the study of Cheung et

al. [5] validating our docking results (Figure S42). Compounds such as β -sitosteryl oleate (**1**) demonstrated the strongest binding score (-10.9898 kcal/mol), though no specific interactions were listed. This can be potentially explained by the bulkiness or hydrophobicity of this compound, which occupied the hydrophobic region of the active gorge effectively. Compounds **4** and **5** showed significant arene-H and π - π stacking interactions with Trp86, respectively (Figures S36, S37). They also showed significant interaction with Tyr341 residue (π - π stacking). These results align with the reported data of these residues as key contributors to ligand binding and stabilization [5]. Interestingly, syringaresinol (**5**) shared donepezil its molecular sizes and several structural features, which can be noticed from their superimposed structures compared to **4** (Figure S43). This result could explain the remarkable higher AChE inhibitory activity of **5** compared to the other tested compounds. Diosmetin (**7**) showed strong interactions with the key amino acid residues of Phe295 (H-bond) and Tyr341 (π - π stacking), which were previously identified as critical residues at the active site of AChE, anchoring diosmetin at the entrance of the active site gorge [5]. This can clarify why diosmetin showed *in vitro* AChE inhibitory activity.

The early evaluation of ADME properties of a potential drug is crucial to ensure its bioavailability and reflects its medicinal chemistry compatibility. The results of analysis of ADME and drug-likeness properties of compounds **1-9** using the SwissADME web tool [7] (Table S8; Figures S44, S45) indicated that compounds **4** and **5** exhibited a balanced profile of solubility, bioavailability, and GI absorption, making them promising candidates for further exploration.

Acknowledgments

The authors extend their appreciation to Prince Sattam bin Abdulaziz University for funding this research work through project number (2023/03/25868). Department of Pharmacognosy and Pharmaceutical Chemistry, College of Dentistry & Pharmacy, Buraydah Colleges is also acknowledged for supporting this research.

Supporting Information

Supporting Information accompanies this paper on <http://www.acgpubs.org/journal/records-of-natural-products>

ORCID

Aalaa Salem: [0000-0001-8182-7437](https://orcid.org/0000-0001-8182-7437)

Fatma M. Abdel Bar: [0000-0003-0823-4015](https://orcid.org/0000-0003-0823-4015)

El-Sayed M. Marwan: [0009-0006-1697-0476](https://orcid.org/0009-0006-1697-0476)

Amal F. Soliman: [0000-0003-3320-0685](https://orcid.org/0000-0003-3320-0685)

Saleh H. El-Sharkawy: [0009-0004-6519-9038](https://orcid.org/0009-0004-6519-9038)

Amira Mira: [0000-0002-4821-7634](https://orcid.org/0000-0002-4821-7634)

References

- [1] Y. H. Dewir, M. E. El-Mahrouk, M. K. Seliem and H. N. Murthy (2020). Bioactive compounds of californian fan palm *Washingtonia filifera* (Linden ex André) H. Wendl. ex de Bary, In *Bioactive compounds in underutilized fruits and nuts*, Murthy, H.N., Bapat, V.A., Eds.; Springer International Publishing: Cham; pp.63-74.
- [2] B. Era, S. Floris, V. Sogos, C. Porcedda, A. Piras, R. Medda, A. Fais and F. Pintus (2021). Anti-aging potential of extracts from *Washingtonia filifera* seeds, *Plants* **10**(1), 151.
- [3] S. Floris, A. Fais, A. Rosa, A. Piras, H. Marzouki, R. Medda, A. M. González-Paramás, A. Kumar, C. Santos-Buelga and B. Era (2019). Phytochemical composition and the cholinesterase and xanthine oxidase inhibitory properties of seed extracts from the *Washingtonia filifera* palm fruit, *RSC Adv.* **9**, 21278-21287.

Compounds from *Washingtonia filifera* as acetylcholinesterase inhibitors

- [4] N. Satheeshkumar, P. K. Mukherjee, S. Bhadra and B. P. Saha (2010). Acetylcholinesterase enzyme inhibitory potential of standardized extract of *Trigonella foenum graecum* L and its constituents, *Phytomed.* **17**(3-4), 292-295.
- [5] J. Cheung, M. J. Rudolph, F. Burshteyn, M. S. Cassidy, E. N. Gary, J. Love, M. C. Franklin and J. J. Height (2012). Structures of human acetylcholinesterase in complex with pharmacologically important ligands, *J. Med. Chem.* **55**(22), 10282-10286.
- [6] F. M. A. Bar, M. Sameti, A. I. Foudah, A. Haque and M. Elsbaey (2022). *In vitro* and *in silico* inhibition of COX-2 and 5-LOX by beta-carboline alkaloids from the seeds of *Peganum harmala* L, *S. Afr. J. Bot.* **147**, 926-936.
- [7] A. Daina, O. Michielin and V. Zoete (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, *Sci. Rep.* **7**, 42717.
- [8] K. Farabi, D. Harneti, N. Nurlelasari, R. Maharani, A. Hidayat, U. Supratman, K. Awang and Y. Shiono (2017). Cytotoxic steroids from the bark of *Aglaia argentea* (Meliaceae), *Chiang Mai Univ. J. Nat. Sci.* **16**, 293-306.
- [9] M. E. Di Pietro, A. Mannu and A. Mele (2020). NMR determination of free fatty acids in vegetable oils, *Processes* **8**(4), 410.
- [10] M. E. El-Beeh, A. A. El-Badawi, S. H. Qari, M. F. Ramadan and W. M. Filfilan (2022). Protective and health-promoting impact of *Washingtonia filifera* oil on the kidney of STZ-induced diabetic mice, *Appl. Biol. Chem.* **65**(1), 41.
- [11] I. A. Nehdi (2011). Characteristics and composition of *Washingtonia filifera* (Linden ex André) H. Wendl. seed and seed oil, *Food Chem.* **126**(1), 197-202.
- [12] R. A. Gomaa (2019). Physico-chemical characteristics of *Washingtonia robusta* Fruit Oil, *Food Sci. Suez Canal Univ.* **6**(1), 19-25.
- [13] H. Jeh-Jian and C. Hung-Cheh (1995). Lignans from the wood of *Aralia bipinnata*, *Phytochemistry* **39**(4), 899-902.
- [14] M. Katsuyoshi, O. Yishan and K. Kazuo (1996). Phenolic Constituents of *Irvingia malayana*, *Nat. Med.* **50**(5), 325-327.
- [15] B.-Y. Yang, X. Yin, Y. Liu, Y. Sun, W. Guan, Y.-Y. Zhou and H.-X. Kuang (2018). Terpenes and lignans from the roots of *Solanum melongena* L, *Nat. Prod. Res.* **34**(3), 359-368.
- [16] W. Monthong, S. Pitchuanom, N. Nuntasen and W. Pompimon (2011). (+)-Syringaresinol lignan from new species *Magnolia thailandica*, *Am. J. Appl. Sci.* **8**(12), 1268-1271.
- [17] Y. Park, B. H. Moon, H. Yang, Y. Lee, E. Lee and Y. Lim (2007). Complete assignments of NMR data of 13 hydroxymethoxyflavones, *Magn. Reson. Chem.* **45**(12), 1072-1075.
- [18] X. X. Liu, S. W. Sun, W. J. Yuan, H. Gao, Y. Y. Si, K. Liu, S. Zhang, Y. Liu and W. Wang (2018). Isolation of tricin as a xanthine oxidase inhibitor from sweet white clover (*Melilotus albus*) and its distribution in selected Gramineae species, *Molecules* **23**(10), 2719.
- [19] C. A. Williams, J. B. Harborne and H. T. Clifford (1973). Negatively charged flavones and tricin as chemosystematic markers in the Palmae, *Phytochemistry* **12**(10), 2417-2430.
- [20] R. M. Silverstein, F. X. Webster and D. J. Kiemle (2005). spectrometric identification of organic compounds, 7th edition ed.; John Wiley.
- [21] C. Boudoukha, H. Bouriche, M. Elmastaş, H. Aksit, O. Kayir, N. Genç and A. Senator (2018). Antioxidant activity of polyphenolic leaf extract from *Santolina chamaecyparissus* L. (Asteraceae) and the isolated luteolin-7-O-glucoside, *J. Pharm. Res. Int.* **22**, 1-12.
- [22] M. Dos Santos Maia, G. C. S. Rodrigues, N. F. de Sousa, M. T. Scotti, L. Scotti and F. J. B. Mendonça-Junior (2020). Identification of new targets and the virtual screening of lignans against Alzheimer's disease, *Oxid. Med. Cell. Longev.* **2020**, 3098673.
- [23] M. A. A. Orabi, R. A. Abdelhamid, H. Elimam, Y. A. M. M. Elshaier, A. A. Ali, N. Aldabaan, A. H. Alhasaniah and M. S. Refaey (2024). Furofuranoid-type lignans and related phenolics from *Anisacanthus virgularis* (Salisb.) Nees with promising anticholinesterase and anti-ageing properties: A study supported by molecular modelling, *Plants* **13**(2), 150.